

# Steven Lentz

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6647281/steven-lentz-publications-by-citations.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

196  
papers

9,328  
citations

55  
h-index

91  
g-index

202  
ext. papers

10,185  
ext. citations

7.6  
avg, IF

6.07  
L-index

#	Paper	IF	Citations
196	Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. <i>Journal of Clinical Investigation</i> , <b>2001</b> , 107, 1263-73	15.9	538
195	Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. <i>Journal of Clinical Investigation</i> , <b>1996</b> , 98, 24-9	15.9	380
194	Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. <i>Journal of Clinical Investigation</i> , <b>1991</b> , 88, 1906-14	15.9	335
193	Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. <i>Immunity</i> , <b>2003</b> , 19, 9-19	32.3	296
192	Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. <i>Cell Death and Differentiation</i> , <b>2004</b> , 11 Suppl 1, S56-64	12.7	280
191	Mechanisms of homocysteine-induced atherothrombosis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2005</b> , 3, 1646-54	15.4	269
190	Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2000</b> , 20, 1557-64	9.4	223
189	Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. <i>Journal of Neuroscience</i> , <b>2007</b> , 27, 2751-9	6.6	188
188	Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine beta-synthase-deficient mice. <i>Circulation Research</i> , <b>2001</b> , 88, 1203-9	15.7	179
187	Homocysteine and its disulfide derivatives: a suggested consensus terminology. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2000</b> , 20, 1704-6	9.4	177
186	Association of multiple cellular stress pathways with accelerated atherosclerosis in hyperhomocysteinemic apolipoprotein E-deficient mice. <i>Circulation</i> , <b>2004</b> , 110, 207-13	16.7	171
185	Critical role for the mitochondrial permeability transition pore and cyclophilin D in platelet activation and thrombosis. <i>Blood</i> , <b>2008</b> , 111, 1257-65	2.2	155
184	Mechanisms of thrombosis in obesity. <i>Current Opinion in Hematology</i> , <b>2013</b> , 20, 437-44	3.3	152
183	Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. <i>Clinical Science</i> , <b>2001</b> , 100, 161-167	6.5	143
182	Fetal hemorrhage and platelet dysfunction in SLP-76-deficient mice. <i>Journal of Clinical Investigation</i> , <b>1999</b> , 103, 19-25	15.9	136
181	Cerebral vascular dysfunction mediated by superoxide in hyperhomocysteinemic mice. <i>Stroke</i> , <b>2004</b> , 35, 1957-62	6.7	135
180	Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , <b>2013</b> , 11, 670-8	15.4	124

179	Single amino acid substitutions dissociate fibrinogen-clotting and thrombomodulin-binding activities of human thrombin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1991</b> , 88, 6775-9	11.5	122
178	Hydrogen peroxide promotes aging-related platelet hyperactivation and thrombosis. <i>Circulation</i> , <b>2013</b> , 127, 1308-16	16.7	113
177	Homocysteine and vascular dysfunction. <i>Life Sciences</i> , <b>1997</b> , 61, 1205-15	6.8	104
176	D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. <i>Annals of Internal Medicine</i> , <b>2015</b> , 162, 27-34	8	96
175	Effect of Mthfr genotype on diet-induced hyperhomocysteinemia and vascular function in mice. <i>Blood</i> , <b>2004</b> , 103, 2624-9	2.2	89
174	Thrombosis of vein grafts: wall tension restrains thrombomodulin expression. <i>Circulation Research</i> , <b>2003</b> , 92, 12-3	15.7	88
173	Deficiency of glutathione peroxidase-1 sensitizes hyperhomocysteinemic mice to endothelial dysfunction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2002</b> , 22, 1996-2002	9.4	86
172	Equilibrium binding of thrombin to recombinant human thrombomodulin: effect of hirudin, fibrinogen, factor Va, and peptide analogues. <i>Biochemistry</i> , <b>1990</b> , 29, 10602-12	3.2	86
171	Perturbations in homocysteine-linked redox homeostasis in a murine model for hyperhomocysteinemia. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , <b>2004</b> , 287, R39-46	3.2	85
170	Human alanine-glyoxylate aminotransferase 2 lowers asymmetric dimethylarginine and protects from inhibition of nitric oxide production. <i>Journal of Biological Chemistry</i> , <b>2010</b> , 285, 5385-91	5.4	84
169	Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA. <i>Atherosclerosis Supplements</i> , <b>2003</b> , 4, 61-5	1.7	83
168	Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site. <i>Blood</i> , <b>2009</b> , 114, 1666-74	2.2	81
167	Murine models of hyperhomocysteinemia and their vascular phenotypes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2008</b> , 28, 1596-605	9.4	80
166	ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice. <i>Blood</i> , <b>2012</b> , 119, 2385-91	2.2	78
165	Enhanced susceptibility to arterial thrombosis in a murine model of hyperhomocysteinemia. <i>Blood</i> , <b>2006</b> , 108, 2237-43	2.2	78
164	Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States. <i>Blood</i> , <b>2016</b> , 127, 2481-8	2.2	76
163	Tissue-specific changes in H19 methylation and expression in mice with hyperhomocysteinemia. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 25506-11	5.4	76
162	Folate dependence of hyperhomocysteinemia and vascular dysfunction in cystathionine beta-synthase-deficient mice. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2000</b> , 279, H970-5	5.2	76

161	Cerebral vascular dysfunction during hypercholesterolemia. <i>Stroke</i> , <b>2007</b> , 38, 2136-41	6.7	75
160	Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 252-261	7	74
159	Homocysteine: is it a clinically important cardiovascular risk factor?. <i>Cleveland Clinic Journal of Medicine</i> , <b>2004</b> , 71, 729-34	2.8	72
158	Glutathione peroxidase-1 plays a major role in protecting against angiotensin II-induced vascular dysfunction. <i>Hypertension</i> , <b>2008</b> , 51, 872-7	8.5	71
157	Results from a large multinational clinical trial (guardianII) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. <i>Haemophilia</i> , <b>2013</b> , 19, 691-7	3.3	70
156	ADAMTS13 deficiency exacerbates VWF-dependent acute myocardial ischemia/reperfusion injury in mice. <i>Blood</i> , <b>2012</b> , 120, 5224-30	2.2	68
155	Overexpression of dimethylarginine dimethylaminohydrolase inhibits asymmetric dimethylarginine-induced endothelial dysfunction in the cerebral circulation. <i>Stroke</i> , <b>2008</b> , 39, 180-4	6.7	67
154	Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. <i>Clinical Science</i> , <b>2001</b> , 100, 161	6.5	66
153	Epigenetic regulation of hepatic endoplasmic reticulum stress pathways in the ethanol-fed cystathionine beta synthase-deficient mouse. <i>Hepatology</i> , <b>2010</b> , 51, 932-41	11.2	65
152	Increased plasma oxidized phospholipid:apolipoprotein B-100 ratio with concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid-lowering: a potential biomarker of early atherosclerosis regression. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2007</b> , 27, 175-81	9.4	65
151	ADAMTS13 reduces VWF-mediated acute inflammation following focal cerebral ischemia in mice. <i>Journal of Thrombosis and Haemostasis</i> , <b>2012</b> , 10, 1665-71	15.4	64
150	Functional domains of membrane-bound human thrombomodulin. EGF-like domains four to six and the serine/threonine-rich domain are required for cofactor activity. <i>Journal of Biological Chemistry</i> , <b>1992</b> , 267, 6164-70	5.4	64
149	Hypermethylation of Fads2 and altered hepatic fatty acid and phospholipid metabolism in mice with hyperhomocysteinemia. <i>Journal of Biological Chemistry</i> , <b>2007</b> , 282, 37082-90	5.4	63
148	Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. <i>Blood</i> , <b>2003</b> , 102, 146-51	11.2	61
147	Structure of cerebral arterioles in cystathionine beta-synthase-deficient mice. <i>Circulation Research</i> , <b>2002</b> , 91, 931-7	15.7	61
146	Thrombomodulin expression by human keratinocytes. Induction of cofactor activity during epidermal differentiation. <i>Journal of Clinical Investigation</i> , <b>1994</b> , 93, 1846-51	15.9	60
145	Consequences of hyperhomocyst(e)inemia on vascular function in atherosclerotic monkeys. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1997</b> , 17, 2930-4	9.4	58
144	Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity. <i>Blood</i> , <b>2002</b> , 99, 437-42	2.2	56

143	Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. <i>Journal of Thrombosis and Haemostasis</i> , <b>2014</b> , 12, 1244-53	15.4	55
142	Alternatively-spliced extra domain A of fibronectin promotes acute inflammation and brain injury after cerebral ischemia in mice. <i>Stroke</i> , <b>2012</b> , 43, 1376-82	6.7	54
141	Cerebral vascular dysfunction in methionine synthase-deficient mice. <i>Circulation</i> , <b>2005</b> , 112, 737-44	16.7	54
140	Hypomorphic mutations in TRNT1 cause retinitis pigmentosa with erythrocytic microcytosis. <i>Human Molecular Genetics</i> , <b>2016</b> , 25, 44-56	5.6	51
139	ADMA and hyperhomocysteinemia. <i>Vascular Medicine</i> , <b>2005</b> , 10 Suppl 1, S27-33	3.3	51
138	Mechanisms of thrombosis in hyperhomocysteinemia. <i>Current Opinion in Hematology</i> , <b>1998</b> , 5, 343-9	3.3	50
137	Critical von Willebrand factor A1 domain residues influence type VI collagen binding. <i>Journal of Thrombosis and Haemostasis</i> , <b>2012</b> , 10, 1417-24	15.4	49
136	ADMA and hyperhomocysteinemia. <i>Vascular Medicine</i> , <b>2005</b> , 10, S27-S33	3.3	48
135	Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2008</b> , 295, H816-25	5.2	47
134	AGXT2: a promiscuous aminotransferase. <i>Trends in Pharmacological Sciences</i> , <b>2014</b> , 35, 575-82	13.2	46
133	Cellular fibronectin containing extra domain A promotes arterial thrombosis in mice through platelet Toll-like receptor 4. <i>Blood</i> , <b>2015</b> , 125, 3164-72	2.2	46
132	Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigmB). <i>Thrombosis Research</i> , <b>2016</b> , 141, 69-76	8.2	46
131	Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. <i>Journal of Thrombosis and Haemostasis</i> , <b>2013</b> , 11, 1300-9	15.4	43
130	Fibronectin Splicing Variants Containing Extra Domain A Promote Atherosclerosis in Mice Through Toll-Like Receptor 4. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2015</b> , 35, 2391-400	9.4	42
129	Testosterone regulation of renal cystathionine beta-synthase: implications for sex-dependent differences in plasma homocysteine levels. <i>American Journal of Physiology - Renal Physiology</i> , <b>2007</b> , 293, F594-600	4.3	42
128	Whole-exome sequencing in evaluation of patients with venous thromboembolism. <i>Blood Advances</i> , <b>2017</b> , 1, 1224-1237	7.8	40
127	Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity. <i>Journal of Thrombosis and Haemostasis</i> , <b>2015</b> , 13, 1989-98	15.4	40
126	Role of FcRgamma and factor XIIIa in coated platelet formation. <i>Blood</i> , <b>2005</b> , 106, 4146-51	2.2	40

125	Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. <i>Blood</i> , <b>2018</b> , 131, 2151-2160	2.2	38
124	Prothrombotic effects of hyperhomocysteinemia and hypercholesterolemia in ApoE-deficient mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2007</b> , 27, 233-40	9.4	38
123	Thrombosis in the setting of obesity or inflammatory bowel disease. <i>Blood</i> , <b>2016</b> , 128, 2388-2394	2.2	38
122	Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa. <i>Haemophilia</i> , <b>2014</b> , 20, 527-34	3.3	37
121	Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 2225-2234	15.4	37
120	Regulation of thrombosis and vascular function by protein methionine oxidation. <i>Blood</i> , <b>2015</b> , 125, 3851-92	2.2	35
119	Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. <i>Clinical Science</i> , <b>2001</b> , 100, 161-7	6.5	35
118	Prostaglandin E1 and Its Analog Misoprostol Inhibit Human CML Stem Cell Self-Renewal via EP4 Receptor Activation and Repression of AP-1. <i>Cell Stem Cell</i> , <b>2017</b> , 21, 359-373.e5	18	32
117	Genetic Ablation of Extra Domain A of Fibronectin in Hypercholesterolemic Mice Improves Stroke Outcome by Reducing Thrombo-Inflammation. <i>Circulation</i> , <b>2015</b> , 132, 2237-47	16.7	31
116	Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. <i>Journal of Thrombosis and Haemostasis</i> , <b>2012</b> , 10, 81-9	15.4	31
115	Dominant negative PPAR $\beta$ promotes atherosclerosis, vascular dysfunction, and hypertension through distinct effects in endothelium and vascular muscle. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , <b>2013</b> , 304, R690-701	3.2	31
114	Overexpression of dimethylarginine dimethylaminohydrolase protects against cerebral vascular effects of hyperhomocysteinemia. <i>Circulation Research</i> , <b>2010</b> , 106, 551-8	15.7	31
113	Expression of TNF-related apoptosis-inducing ligand (TRAIL) in megakaryocytes and platelets. <i>Experimental Hematology</i> , <b>2004</b> , 32, 1073-81	3.1	31
112	Effect of hyperhomocysteinemia on protein C activation and activity. <i>Blood</i> , <b>2002</b> , 100, 2108-12	2.2	31
111	Squamous cell carcinoma in epidermolysis bullosa. Treatment with systemic chemotherapy. <i>Cancer</i> , <b>1990</b> , 66, 1276-8	6.4	31
110	Supplementation of atherogenic diet with B vitamins does not prevent atherosclerosis or vascular dysfunction in monkeys. <i>Circulation</i> , <b>2001</b> , 103, 1006-11	16.7	30
109	Regulation of thrombomodulin by tumor necrosis factor-alpha: comparison of transcriptional and posttranscriptional mechanisms. <i>Blood</i> , <b>1991</b> , 77, 542-50	2.2	30
108	Safety and efficacy of turoctocog alfa (NovoEight $\square$ ) during surgery in patients with haemophilia A: results from the multinational guardian $\square$ clinical trials. <i>Haemophilia</i> , <b>2015</b> , 21, 34-40	3.3	29

107	Paradoxical absence of a prothrombotic phenotype in a mouse model of severe hyperhomocysteinemia. <i>Blood</i> , <b>2012</b> , 119, 3176-83	2.2	29
106	Impaired anticoagulant response to infusion of thrombin in atherosclerotic monkeys associated with acquired defects in the protein C system. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1999</b> , 19, 1744-50	9.4	29
105	Mechanisms of the atherogenic effects of elevated homocysteine in experimental models. <i>Seminars in Vascular Medicine</i> , <b>2005</b> , 5, 163-71		28
104	Does Homocysteine Promote Atherosclerosis?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2001</b> , 21, 1385-1386	9.4	28
103	Endothelial PPAR- $\alpha$ protects against vascular thrombosis by downregulating P-selectin expression. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2015</b> , 35, 838-44	9.4	26
102	Role of hydrogen peroxide and the impact of glutathione peroxidase-1 in regulation of cerebral vascular tone. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2009</b> , 29, 1130-7	7.3	26
101	Malate dehydrogenase: isolation from E. coli and comparison with the eukaryotic mitochondrial and cytoplasmic forms. <i>Bioscience Reports</i> , <b>1981</b> , 1, 497-507	4.1	26
100	Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial). <i>Haemophilia</i> , <b>2019</b> , 25, 373-381	3.3	25
99	Effect of mechanical ventilation on carotid artery thrombosis induced by photochemical injury in mice. <i>Journal of Thrombosis and Haemostasis</i> , <b>2003</b> , 1, 2669-74	15.4	25
98	Influence of folate on arterial permeability and stiffness in the absence or presence of hyperhomocysteinemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2006</b> , 26, 814-8	9.4	24
97	Smooth muscle cell-specific fibronectin-EDA mediates phenotypic switching and neointimal hyperplasia. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 295-314	15.9	24
96	Expression of thrombomodulin and consequences of thrombomodulin deficiency during healing of cutaneous wounds. <i>American Journal of Pathology</i> , <b>1999</b> , 155, 1569-75	5.8	23
95	Cellular localization of thrombomodulin in human epithelium and squamous malignancies. <i>American Journal of Pathology</i> , <b>1995</b> , 146, 933-43	5.8	23
94	Recurrent neuroendocrine (Merkel cell) carcinoma of the skin presenting as marrow failure in a man with systemic lupus erythematosus. <i>Medical and Pediatric Oncology</i> , <b>1993</b> , 21, 137-41		22
93	Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d-dimer results; A cohort study. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 1144-1152	15.4	21
92	Targeting Myeloid-Specific Integrin $\alpha$ <sub>IIb</sub> Improves Short- and Long-Term Stroke Outcomes in Murine Models With Preexisting Comorbidities by Limiting Thrombosis and Inflammation. <i>Circulation Research</i> , <b>2020</b> , 126, 1779-1794	15.7	21
91	ApoA-I: a missing link between homocysteine and lipid metabolism?. <i>Circulation Research</i> , <b>2006</b> , 98, 431-35.7		21
90	Is Homoarginine a Protective Cardiovascular Risk Factor?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2019</b> , 39, 869-875	9.4	20

89	Functional Interactions Between the Thrombin Receptor and the T-Cell Antigen Receptor in Human T-Cell Lines. <i>Blood</i> , <b>1997</b> , 90, 1893-1901	2.2	20
88	Nox2 NADPH oxidase is dispensable for platelet activation or arterial thrombosis in mice. <i>Blood Advances</i> , <b>2019</b> , 3, 1272-1284	7.8	20
87	The nutrigenetics of hyperhomocysteinemia: quantitative proteomics reveals differences in the methionine cycle enzymes of gene-induced versus diet-induced hyperhomocysteinemia. <i>Molecular and Cellular Proteomics</i> , <b>2010</b> , 9, 471-85	7.6	19
86	Role of redox reactions in the vascular phenotype of hyperhomocysteinemic animals. <i>Antioxidants and Redox Signaling</i> , <b>2007</b> , 9, 1899-909	8.4	19
85	Role of the adapter protein SLP-76 in GPVI-dependent platelet procoagulant responses to collagen. <i>Blood</i> , <b>2002</b> , 100, 2839-44	2.2	19
84	Prospective, multicenter study of postoperative deep-vein thrombosis in patients with haemophilia undergoing major orthopaedic surgery. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, 42-9	7	19
83	Remission after 13-cis retinoic acid in thrombotic thrombocytopenic purpura. <i>Lancet, The</i> , <b>1998</b> , 352, 454-5	4.0	17
82	Anticoagulant responses to thrombin are enhanced during regression of atherosclerosis in monkeys. <i>Circulation</i> , <b>2002</b> , 106, 842-6	16.7	17
81	Effects of 1,2-dimethoxyethane on the catalytic and coenzyme properties of glycogen phosphorylase. <i>Biochemistry</i> , <b>1981</b> , 20, 2537-44	3.2	17
80	Sequences required for thrombomodulin cofactor activity within the fourth epidermal growth factor-like domain of human thrombomodulin. <i>Journal of Biological Chemistry</i> , <b>1993</b> , 268, 15312-7	5.4	17
79	A novel ELISA for mouse activated protein C in plasma. <i>Journal of Immunological Methods</i> , <b>2006</b> , 314, 174-81	2.5	16
78	Structure-function relationships of the thrombin-thrombomodulin interaction. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , <b>1993</b> , 23 Suppl 1, 183-93		16
77	Protein methionine oxidation augments reperfusion injury in acute ischemic stroke. <i>JCI Insight</i> , <b>2016</b> , 1,	9.9	16
76	Deficiency of superoxide dismutase promotes cerebral vascular hypertrophy and vascular dysfunction in hyperhomocysteinemia. <i>PLoS ONE</i> , <b>2017</b> , 12, e0175732	3.7	16
75	Prothrombotic States that Predispose to Stroke. <i>Current Treatment Options in Neurology</i> , <b>2002</b> , 4, 417-424	5.4	15
74	Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum. <i>Blood</i> , <b>1993</b> , 81, 683-9	2.2	15
73	ADAMTS13 Retards Progression of Diabetic Nephropathy by Inhibiting Intrarenal Thrombosis in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2017</b> , 37, 1332-1338	9.4	14
72	Fibronectin Containing Extra Domain A Induces Plaque Destabilization in the Innominate Artery of Aged Apolipoprotein E-Deficient Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2018</b> , 38, 500-508	8.4	13



71	The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2018</b> , 16, 352-363	15.4	13
70	Protective vascular and cardiac effects of inducible nitric oxide synthase in mice with hyperhomocysteinemia. <i>PLoS ONE</i> , <b>2014</b> , 9, e107734	3.7	13
69	Thrombosis in the setting of obesity or inflammatory bowel disease. <i>Hematology American Society of Hematology Education Program</i> , <b>2016</b> , 2016, 180-187	3.1	13
68	Deficiency of superoxide dismutase impairs protein C activation and enhances susceptibility to experimental thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2015</b> , 35, 1798-804	9.4	12
67	Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial. <i>Haemophilia</i> , <b>2018</b> , 24, e391-e394	3.3	12
66	Keratinocyte-specific expression of human thrombomodulin in transgenic mice: effects on epidermal differentiation and cutaneous wound healing. <i>Journal of Investigative Medicine</i> , <b>1998</b> , 46, 127-33	2.9	12
65	Memantine Protects From Exacerbation of Ischemic Stroke and Blood Brain Barrier Disruption in Mild But Not Severe Hyperhomocysteinemia. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e013368	6	11
64	D-dimer levels and recurrence in patients with unprovoked VTE and a negative qualitative D-dimer test after treatment. <i>Thrombosis Research</i> , <b>2016</b> , 146, 119-125	8.2	11
63	Clinical and laboratory phenotype variability in type 2M von Willebrand disease. <i>Journal of Thrombosis and Haemostasis</i> , <b>2017</b> , 15, 1559-1566	15.4	10
62	Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , <b>2017</b> , 15, 1971-1976	15.4	10
61	Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight(®)) in previously treated patients with severe haemophilia A: interim results of the guardian(®)2 extension trial. <i>Haemophilia</i> , <b>2015</b> , 21, e436-9	3.3	10
60	Durable responses to rituximab in acquired factor VIII deficiency. <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 106, 172-4	7	10
59	Hyperhomocysteinemia increases arterial permeability and stiffness in mice. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , <b>2006</b> , 291, R1349-54	3.2	10
58	Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2019</b> , 3, 542-554 <sup>1</sup>	5.1	9
57	Another lesson from the factor V Leiden mouse: thrombin generation drives arterial disease. <i>Circulation</i> , <b>2005</b> , 111, 1733-4	16.7	9
56	Posttranslational modification of the carboxy-terminal region of the beta subunit of human chorionic gonadotropin. <i>Biochemistry</i> , <b>1984</b> , 23, 5330-7	3.2	9
55	Smooth Muscle Cell-Specific PKM2 (Pyruvate Kinase Muscle 2) Promotes Smooth Muscle Cell Phenotypic Switching and Neointimal Hyperplasia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2021</b> , 41, 1724-1737	9.4	9
54	Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm(®) trials. <i>Haemophilia</i> , <b>2018</b> , 24, 911-920	3.3	9

53	Helicopter "Drip and Ship" Flights Do Not Alter the Pharmacological Integrity of rtPA. <i>Journal of Stroke and Cerebrovascular Diseases</i> , <b>2018</b> , 27, 2720-2724	2.8	8
52	Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1). <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 341-351	15.4	8
51	Deletion of Methionine Sulfoxide Reductase A Does Not Affect Atherothrombosis but Promotes Neointimal Hyperplasia and Extracellular Signal-Regulated Kinase 1/2 Signaling. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2015</b> , 35, 2594-604	9.4	7
50	Human thrombomodulin knock-in mice reveal differential effects of human thrombomodulin on thrombosis and atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2011</b> , 31, 2509-17	9.4	7
49	Interim results from a large multinational extension trial (guardian(II)) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A. <i>Haemophilia</i> , <b>2016</b> , 22, e445-9	3.3	6
48	Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials. <i>Haemophilia</i> , <b>2020</b> , 26, 450-458	3.3	6
47	A novel supplemental approach to capturing post-marketing safety information on recombinant factor VIIIa in acquired hemophilia: the Acquired Hemophilia Surveillance project. <i>Journal of Blood Medicine</i> , <b>2014</b> , 5, 1-3	2.3	5
46	Dok-1 negatively regulates platelet integrin $\alpha$ IIb $\beta$ 3 outside-in signalling and inhibits thrombosis in mice. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 115, 969-78	7	5
45	The metabolic enzyme pyruvate kinase M2 regulates platelet function and arterial thrombosis. <i>Blood</i> , <b>2021</b> , 137, 1658-1668	2.2	5
44	Factor VIII Dosing and Preventive Efficacy in Obese Patients with Hemophilia (BMI $\geq 30$ kg/m <sup>2</sup> ) $\square$ Post-Hoc Sub-Analysis of the guardian $\square$ Trials. <i>Blood</i> , <b>2014</b> , 124, 1503-1503	2.2	4
43	Regulation of thrombomodulin expression by all-trans retinoic acid and tumor necrosis factor- $\alpha$ : differential responses in keratinocytes and endothelial cells. <i>Blood</i> , <b>1996</b> , 88, 2043-9	2.2	4
42	Case report: paroxysmal cold hemoglobinuria presenting during pregnancy. <i>BMC Hematology</i> , <b>2015</b> , 15, 3	2.5	3
41	Bleeding from Acquired Coagulation Defects and Antithrombotic Therapy		3
40	Fibrin films: overlooked hemostatic barriers against microbial infiltration. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 3243-3245	15.9	3
39	Cerebral Vascular Dysfunction in Methionine Synthase-Deficient Mice.. <i>Blood</i> , <b>2004</b> , 104, 2617-2617	2.2	3
38	Genetic testing to guide warfarin dosing: Impact of direct oral anticoagulants. <i>Clinical Pharmacology and Therapeutics</i> , <b>2016</b> , 100, 128-30	6.1	3
37	Cooling down VITT with IVIG. <i>Blood</i> , <b>2021</b> , 138, 921-922	2.2	3
36	Turoctocog alfa and drug development for hemophilia A. <i>Expert Opinion on Orphan Drugs</i> , <b>2014</b> , 2, 419-431	4.1	2

35	The benefits of excess EPCR. <i>Journal of Thrombosis and Haemostasis</i> , <b>2005</b> , 3, 1349-50	15.4	2
34	Postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery: A prospective multicenter observational study.. <i>Journal of Thrombosis and Haemostasis</i> , <b>2022</b> ,	15.4	2
33	ADAMTS13 Deficiency Exacerbates VWF-Dependent Acute Myocardial Ischemia/Reperfusion Injury in Mice. <i>Blood</i> , <b>2012</b> , 120, 264-264	2.2	2
32	Hyperhomocysteinemic Mice Have Increased Susceptibility to Carotid Artery Thrombosis.. <i>Blood</i> , <b>2004</b> , 104, 2616-2616	2.2	2
31	Whole Exome Sequencing and Extended Thrombophilia Testing in Patients with Venous Thromboembolism. <i>Blood</i> , <b>2018</b> , 132, 2506-2506	2.2	2
30	The emerging role of asymmetric dimethylarginine in cardiovascular disease. <i>Arterial Hypertension (Russian Federation)</i> , <b>2008</b> , 14, 306-314	0.7	2
29	Letter by Sonkar et al Regarding Article, "Class III PI3K Positively Regulates Platelet Activation and Thrombosis via PI(3)P-Directed Function of NADPH Oxidase". <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2018</b> , 38, e25	9.4	1
28	The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data from the ADEPT2 trial. <i>Blood Coagulation and Fibrinolysis</i> , <b>2017</b> , 28, 224-229	1	1
27	Countervailing effects on atherogenesis and plaque stability: a paradoxical benefit of hypercoagulability?. <i>Circulation</i> , <b>2009</b> , 120, 722-4	16.7	1
26	Many Potential Explanations for the Homocysteine Paradox. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2008</b> , 28,	9.4	1
25	Prospective Diagnosis of VWD in a Large Cohort of Patients with Bleeding Symptoms through the Zimmerman Program. <i>Blood</i> , <b>2018</b> , 132, 979-979	2.2	1
24	Surgery with Turoctocog Alfa: Efficacy and Safety in Bleeding Prevention During Surgical Procedures - Results From the guardianTrials.. <i>Blood</i> , <b>2012</b> , 120, 2228-2228	2.2	1
23	Safety and Efficacy of Nonacog Beta Pegol (N9-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously-Treated Patients with Hemophilia B: Results from an Extension Trial. <i>Blood</i> , <b>2014</b> , 124, 2846-2846	2.2	1
22	Thrombotic potential during pediatric acute lymphoblastic leukemia induction: Role of cell-free DNA. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2021</b> , 5, e12557	5.1	1
21	Myeloid Cell PKM2 Deletion Enhances Efferocytosis and Reduces Atherosclerosis.. <i>Circulation Research</i> , <b>2022</b> , 101161CIRCRESAHA121320704	15.7	1
20	On PAR with aPC to target inflammasomes. <i>Blood</i> , <b>2017</b> , 130, 2579-2581	2.2	0
19	Homocysteine <b>2015</b> , 53-62		
18	Pilot trial of semi-automated medical note writing using lexeme hypotheses. <i>International Journal of Medical Informatics</i> , <b>2020</b> , 136, 104095	5.3	

17	Haemophilia clinical care and research needs: Assessing priorities. <i>Haemophilia</i> , <b>2018</b> , 24, e270-e273	3.3
16	Targeting platelet EPCR for better therapeutic factor VIIIa activity. <i>Journal of Thrombosis and Haemostasis</i> , <b>2018</b> , 16, 1814-1816	15.4
15	Trends in clinical laboratory homocysteine testing from 1997 to 2010: the impact of evidence on clinical practice at a single institution. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2013</b> , 51, 671-5	5.9
14	Electronic communication at arteriosclerosis, thrombosis, and vascular biology. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2000</b> , 20, 1851	9.4
13	Interference in protein C activation assays from endogenous serpins in mammalian host cells. <i>Thrombosis Research</i> , <b>1996</b> , 84, 373-7	8.2
12	Atherosclerotic vascular disease: will folate or gene therapy be useful?. <i>Transactions of the American Clinical and Climatological Association</i> , <b>1997</b> , 108, 69-76; discussion 76-7	0.9
11	TNF Family Protein Regulation in Megakaryocytes and Platelets.. <i>Blood</i> , <b>2005</b> , 106, 4250-4250	2.2
10	Overexpression of DDAH-1 in mice inhibits effects of ADMA on endothelial function in the cerebral circulation.. <i>FASEB Journal</i> , <b>2006</b> , 20, A731	0.9
9	Genetic Evidence that Cerebrovascular Responses to Arachidonic Acid are Mediated by Hydrogen Peroxide Produced by SOD-1. <i>FASEB Journal</i> , <b>2007</b> , 21, A1384	0.9
8	the NADPH Oxidase Catalytic Subunit Nox2 Displays Differential Roles in Arterial Vs. Venous Thrombosis. <i>Blood</i> , <b>2016</b> , 128, 4907-4907	2.2
7	The Acquired Hemophilia Surveillance (AHS) Project: A Novel Mechanism of Capturing Post-Marketing Safety Information on rFVIIa (NovoSeven® RT) In Acquired Hemophilia.. <i>Blood</i> , <b>2010</b> , 116, 3674-3674	2.2
6	Durable Responses to Rituximab In Acquired Factor VIII Deficiency.. <i>Blood</i> , <b>2010</b> , 116, 3680-3680	2.2
5	EDA-Containing Fibronectin Aggravates Ischemic Brain Injury In Mice. <i>Blood</i> , <b>2010</b> , 116, 330-330	2.2
4	A Novel Approach to Capturing Post-Marketing Safety Information On Recombinant Factor VIIa (rFVIIa) in Acquired Hemophilia: Final Data From the Acquired Hemophilia Surveillance (AHS) Project. <i>Blood</i> , <b>2012</b> , 120, 3371-3371	2.2
3	ADAMTS13 Reduces Vascular Inflammation and Early Development of Atherosclerosis Via VWF-Dependent Mechanism.. <i>Blood</i> , <b>2012</b> , 120, 2178-2178	2.2
2	Dissecting The Effects Of Isoprenoid Pathway Inhibition On Hemostasis and Thrombosis: Differential Effects Of Atorvastatin and Digeranyl Bisphosphonate In Hypercholesterolemic Mice. <i>Blood</i> , <b>2013</b> , 122, 2378-2378	2.2
1	Turoctocog alfa pegol (N8-GP) in severe hemophilia A: Long-term safety and efficacy in previously treated patients of all ages in the pathfinder8 study.. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2022</b> , 6, e12674	5.1